- 询价
- AntibodySystem
- DHH34799
- France
- 2025年07月11日
- Research Grade Biosimilar
- Human
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 抗体名：
Murlentamab-MMAE (ADC)
- 抗体英文名：
Murlentamab-MMAE (ADC)
- 浓度：
1 mg/ml
- 应用范围：
Research Grade Biosimilar
- 适应物种：
Human
- 保质期：
1 year
- 级别：
科研级
- 库存：
999
- 供应商：
AntibodySystem
- 克隆性：
Monoclonal
- 保存条件：
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
- 形态：
Liquid
- 规格：
100ug
| 描述 | Murlentamab-MMAE is an ADC consisting of an AMHR2-directed antibody and Monomethyl auristatin E (MMAE) used for the study of colorectal cancer and ovarian cancer. |
| 种属反应性 | Human |
| 状态 | Liquid |
| 浓度 | 1 mg/ml |
| 纯度 | >90% as determined by SEC. |
| 克隆类型 | Monoclonal |
| 应用 | Research Grade Biosimilar |
| 靶标 | MIS type II receptor, MISR2, AMHR2, AMHR, Anti-Muellerian hormone type II receptor, MRII, AMH type II receptor, MISRII, Anti-Muellerian hormone type-2 receptor |
| 纯化方式 | Purified by Ion Exchange Chromatography. |
| 内毒素水平 | Please contact with the lab for this information. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| 克隆号 | Murlentamab-MMAE |
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
Our products are designed for various research areas, supporting studies on 48 types of viruses, superbugs, parasites, cancer, Alzheimer's disease, Parkinson's disease, allergic responses, immune suppression, and immune activation.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验MMAE (HY-15162) www.medchemexpress.cn/Monomethyl-auristatin-E.html ADC Payload Dxd (HY-13631D) www.medchemexpress.cn/Dxd.html ADC Payload Exatecan (HY-13631) www.medchemexpress.cn/exatecan.html ADC Payload
AntibodyDrug Conjugate (ADC) Clinical Pipeline: A Review
them to small molecule drugs. This combination is expected to bring together the benefits of highly potent drugs on the one hand and selective binders of specific tumor antigens on the other hand. However, designing an ADC is more complex than a simple meccano
国产CLDN18.2 ADC申报上市，晚期胃癌靶向治疗迎来新格局
胃癌是我国高发恶性肿瘤，新发病例占全球逾三分之一，晚期患者中位总生存期不足10个月，多线治疗后可选方案极为有限。在这一严峻背景下，CLDN18.2作为继HER2之后胃癌领域最具潜力的治疗靶点，备受关注。然而，全球已上市的CLDN18.2靶向疗法仅安斯泰来的单抗Zolbetuximab（2024年日本获批）和科济药业的CAR-T产品，前者单药缓解能力有限，后者成本高昂普及困难，临床仍亟需兼顾精准性与强效杀伤的ADC方案。2026年6月23日，中国生物制药旗下正大天晴的维特柯妥拜单抗（LM-302
技术资料暂无技术资料 索取技术资料
